Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

Background Anetumab ravtansine (BAY 94-9343) is a novel fully human anti-mesothelin
IgG1 antibody conjugated to the maytansinoid tubulin inhibitor DM4. We report the results of …

Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We
aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab …

Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Background There is a strong unmet need to improve systemic therapy in mesothelioma.
Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural …

Introduction There is a strong theoretical rationale for combining checkpoint blockade with
cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm …

Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …

8507 Background: All patients with malignant pleural mesothelioma (MPM) eventually
relapse following standard chemotherapy. However, there is no standard treatment option in …

Introduction Mesothelioma often presents with a high vessel count and increased vascular
growth factors levels. Interference with angiogenesis may therefore improve outcome. This …

PURPOSE Antiangiogenic agents combined with chemotherapy have efficacy in the
treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca …